• Radiation Oncology Journal
• /
• 제21권2호
• /
• pp.158-166
• /
• 2003

목적: 본 연구는 새로운 근접치료선원의 이론적 설계를 통해 출력변조를 이용한 혈관내 방사선치료를 제안한다. 대상 및 방법: 제시된 이론적 선원은 기존의 선원과는 달리 선원물질과 차폐물질(스테인리스 스틸, 또는 텅스텐) 둘 다로 구성되며 이는 방위방향으로 비대칭적 방사선량을 제공할 수 있게 한다. 따라서, 방위방향으로 선원의 방향과 체류시간을 조절함으로써 출력변조를 통한 근접치료가 가능해진다. Novoste Beta-Cath system에서 사용하는 Sr-90/Y 전자방출 선원과 유사한 모양의 두 가지 단순화한 선원을 연구의 대상으로 고려하였다. 첫 번째 선원은 선원물질과 차폐물질이 각각 반씩 차지하며, 두 번째 선원은 1/4은 선원물질로, 나머지 3/4은 차폐물질로 구성된다. 두 선원에 대해 방위 및 방사방향으로의 선량분포를 MCNP 몬테 카를로 코드를 이용하여 계산하였다. 결과: 선원이 혈관내의 중심에 위치하지 않게 되는 가상조건에서의 선량 최적화 계산을 시도한 결과, 혈관내벽에 미치는 선량의 최고치와 최저치의 차이가 87$\%$에서 7$\%$까지 줄어들 수 있음을 보였다. 결론: 본 연구에서 제시된 이론적 선원은 선량적 관점에서의 적합성 여부에 관해 매우 고무적인 결과를 보여 줌으로써 출력변조를 통한 혈관내 근접방사선치료의 가능성을 나타내었다. 본 과제의 다음 단계는 굵기가 가는 맥관 내에서 선원의 위치를 파악하여 그를 방위방향으로 정확하게 회전시킬 수 있는 방사선 전달 체계의 개발이라 할 수 있다.

• 한국원자력학회:학술대회논문집
• /
• 한국원자력학회 2005년도 추계학술발표회
• /
• pp.759-760
• /
• 2005

• 대한핵의학회:학술대회논문집
• /
• 대한핵의학회 1999년도 제38차 춘계학술대회
• /
• pp.228-241
• /
• 1999

Percutaneous coronary angioplasty is well established therapeutic modality in the management of coronary artery disease. However, the high restenosis rate of 30 to 50% limits its usefulness. The principal mechanism of restenosis, intimal hyperplasia, is the proliferative response of vessel wall to injury, which consists largely of smooth muscle cells. A large body of animal investigations and a limited number of clinical studies have established the ability of ionizing radiation to reduce neointimal proliferation and restenosis rate significantly. Human studies have been reported that intravascular radiation after first restenosis inhibits a second restenosis. Encouraged by these reports, we are also conducting a double blind, placebo-controlled, randomized trial to evaluate this new therapeutic modality in patients with coronary artery stenosis. The objective of our trial is to determine the safety and efficacy of catheter-based solutional beta emitting radioisotope system in preventing restenosis after angioplasty. This review describes the vascular brachytherapy systems and isotopes that have been utilized in the initial clinical trials performed in this area of post PTCA coronary restenosis. The results of many worldwide ongoing clinical trials will determine whether this new technology will change the future practice of vascular intervention.

• Asian Pacific Journal of Cancer Prevention
• /
• 제13권4호
• /
• pp.1487-1489
• /
• 2012

Objective: To compare the clinical efficacy of concurrent chemoradiotherapy, neoadjuvant chemotherapy, and intracavity brachytherapy in comprehensive treatment for young patients with stage Ib2 cervical cancer. Methods: One hundred and twelve young patients with stage Ib2 cervical cancer were enrolled retrospectively in our hospital from January 2003 to June 2005. They were categorized into three groups according to preoperative regimens, including the concurrent chemoradiotherapy group (Group 1, n=38), the neoadjuvant chemotherapy (Group 2, n=49), and the intracavity brachytherapy group (Group 3, n=25). Radical hysterectomy was performed following these regimens. Chemotherapy and radiotherapy were given according to pelvic lymph node metastasis, deep cervical stromal invasion, intravascular cancer emboli, histological grading, vaginal stump and positive surgical margin. Results: The cancer disappearance and superficial muscle invasion rates were statistically significantly better in the concurrent chemoradiotherapy group than in the other two groups (P<0.01). No statistically significant difference was noted in the deep muscle invasion rate, surgical time and intraoperative blood loss among three groups, but significantly more postoperative complications occurred in the concurrent chemoradiotherapy group. The 2-year pelvic recurrence was statistically significantly lower in the concurrent chemoradiotherapy group compared to other two groups, while the 5-year survival was higher. Conclusion: Concurrent chemoradiotherapy is efficacious for young patients with stage Ib2 cervical cancer.